https://www.thebodypro.com/author/david-alain-wohl
David Alain Wohl, M.D. Img

David Alain Wohl, M.D.

David Alain Wohl, M.D., is a professor of medicine in the Division of Infectious Diseases at the University of North Carolina (UNC). He is site leader of the UNC AIDS Clinical Trials Unit at Chapel Hill, director of the North Carolina AIDS Education and Training Center (AETC), and co-director of HIV services for the North Carolina state prison system. In 2014, he became co-director of the UNC-Duke Clinical RM Ebola Response Consortium.

Dr. Wohl's research aims to optimize the treatment of HIV, including identifying the most effective therapeutic approaches and minimizing the adverse effects of therapy. He is also active in investigations focused on populations vulnerable to HIV, such as the incarcerated. He is active within the U.S. AIDS Clinical Trials Group and HIV Prevention Trials Network and served two terms as a member of the U.S. Department of Health and Human Services Antiretroviral Guidelines Panel.

As part of the response to the 2013-2016 Ebola outbreak in West Africa, Dr. Wohl led UNC clinical research efforts to test interventions for Ebola Virus Disease in Liberia and now directs a clinical cohort of Ebola survivors.

In addition to his research and administrative activities, Dr. Wohl maintains a large HIV continuity clinic at UNC.

Disclosures

Dr. Wohl has attended advisory boards for Abbott Laboratories, Tibotec, Janssen Pharmaceuticals, ViiV Healthcare, and Gilead Sciences. In addition, his university has received support for his research from Gilead Sciences and ViiV Healthcare. These disclosures were last updated on November 17, 2017.

Latest by David Alain Wohl, M.D.

photo of David Alain Wohl, M.D., as he recaps research from CROI 2021
Conference Coverage

As CROI 2021 Attests, the PrEP Revolution Is Coming

Analysis from David Alain Wohl, M.D., on new research in on HIV prevention, especially in areas that will expand and transform PrEP options.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021
Conference Coverage

Broadly Neutralizing Antibodies for HIV? If We Can Do It for COVID ...

David Alain Wohl, M.D., shares his thoughts on broadly neutralizing antibodies for COVID-19—and the extent to which we can hope to see similar developments in HIV.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021
Conference Coverage

Sleep and Diet: Don’t Underestimate Their Importance for People Living With HIV

David Alain Wohl, M.D., on new findings from CROI 2021 that help us better understand the connections between sleep, diet, and quality of life among people living with HIV.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021
Conference Coverage

CROI 2021 Takeaway: Long-Acting Antiretrovirals for HIV Treatment

David Alain Wohl, M.D., talks through new data regarding long-acting antiretroviral therapy for HIV—and touches on the uncertainties clinicians face in incorporating this new treatment method into their practice.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps research from CROI 2021
Conference Coverage

Hypertension Control Emerges as Key Concern in Examination of HIV, Aging, and Cardiovascular Disease

David Alain Wohl, M.D., talks through new data presented at CROI 2021 that further our understanding of the interplay between HIV and comorbidities we often associate with aging, particularly those related to cardiovascular disease.

By David Alain Wohl, M.D.
photo of David Alain Wohl, M.D., as he recaps COVID-19 research from CROI 2021
Conference Coverage

HIV & COVID-19: CROI 2021 Reveals New Research

David Alain Wohl, M.D., analyzes updated data regarding the intersection of HIV and COVID-19, with a particular focus on SARS-CoV-2 susceptibility and disease severity.

By David Alain Wohl, M.D.
triptych of medical scientists performing lab and research duties
Features

Top 10 HIV Clinical Developments of 2020

In this exclusive series of articles, David Alain Wohl, M.D., calls attention to 10 developments that have tremendous short-term implications for our day-to-day efforts to improve HIV prevention, treatment, patient care, and policy in the U.S., and analyzes each development with his trademark wit and clinical savvy.

By David Alain Wohl, M.D.
COVID-19 mask
Features

HIV in the Time of COVID-19

While we remain uncertain about the precise level of interaction (if any) between HIV and SARS-CoV-2 on a pathophysiological level, the pandemic’s disruption of HIV care is irrefutable.

By David Alain Wohl, M.D.
intramuscular injection
Features

HIV PrEP Is Finally About to Get Its Shot

PrEP for HIV is a pill. It has always been a pill. But it will not always be a pill, thanks to two major trials evaluating cabotegravir, an integrase inhibitor formulated for intramuscular injection, as PrEP.

By David Alain Wohl, M.D.
prescription bottle
Features

PrEP and Prior Authorization: A Discriminatory Cheap Ploy

An important new analysis describes a key barrier to PrEP in the U.S., one that is almost sinister in its application predominantly in southern states.

By David Alain Wohl, M.D.